Are ICER publications having an impact on drug price acceptability in the US?

The Institute for Clinical and Economic Review (ICER) is a US lobby group that looks at the clinical benefit of value-added drugs and recommends “cost-effective” prices. Their definition of cost-effectiveness is not a hard barrier, such as the one used by NICE in the UK, but is a range of thresholds, the highest of which is 200 000 USD per quality-adjusted life year (QALY). Pharmaceutical executives are interested in whether ICER’s publications are impacting their drugs’ price acceptability.

Back to White Papers

Download the document by filling in the form:

By clicking on the “Submit Request” button you are providing consent for us to store your data and contact you. You may withdraw your consent at any time by instructing us at .

View our Privacy Policy for more information.

Please note that Inpharmation literature and case study materials constitute Inpharmation intellectual property and are intended for the pharmaceutical industry. Inpharmation is under no obligation to distribute these materials to non-pharmaceutical industry employees or competitors.

Scroll Top